August 15, 2019 Bayer provides produce growers with holistic approach to field challenges during first ever Agriculture and Innovation ShowcaseDe Ruiter and Seminis seed brands discuss sustainable and tailored solutions / Industry collaborators demonstrate new advances in digital automation technology ...Read more
August 8, 2019 Bayer acquires BlueRock Therapeutics to build leading position in cell therapyImplied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer ...Read more
August 6, 2019 Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructure and Real AssetsCurrenta valued with an attractive enterprise value of EUR 3.5 billion (100%) ...Read more
SPECIALIZED PRESS July 31, 2019 Not intended for U.S. and UK MediaU.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancerDarolutamide was approved in the U.S. under the FDA Priority Review designation ...Read more
July 30, 2019 Second quarter of 2019:Bayer on track in operational businessGroup sales increase by 0.9 percent (Fx & portfolio adj.) to 11.485 billion euros ...Read more
SPECIALIZED PRESS July 26, 2019 Not intended for U.S. and UK MediaBayer receives positive CHMP opinion for precision oncology treatment larotrectinib with first ever tumor-agnostic indication in in EuropeRecommendation for approval for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion ...Read more
July 24, 2019 Bayer and White Ribbon Alliance announce three-year renewal of partnership to improve the every day health of women, infants and children through self-careBayer and White Ribbon Alliance efforts have engaged more than 90 communities to take self-care actions and increase utilization of vital health services ...Read more
SPECIALIZED PRESS July 18, 2019 Not intended for U.S. and UK MediaBayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with colorectal cancerCombination of regorafenib and nivolumab vs. regorafenib alone to be evaluated in patients with micro-satellite stable metastatic colorectal cancer ...Read more
July 17, 2019 Pyxis Oncology Founded by Longwood Fund with Financing Led by BayerBuilding on New Insights in Tumor Biology Discovered by Award-winning Cancer Researcher Thomas Gajewski, MD, PhD / USD 22 Million Series A to Fund Pipeline of Antibodies Focused on Novel Immuno-oncology Targets ...Read more
